



Glenmark – Recall of ranitidine

- On December 17, 2019, the [FDA announced](#) a voluntary, consumer-level recall of prescription [ranitidine](#) due to potential N-nitrosodimethylamine (NDMA) amounts above levels established by the FDA, based on FDA-validated tests.
- NDMA is classified as a probable human carcinogen based on results from laboratory tests. NDMA is a known environmental contaminant and found in water and foods, including meats, dairy products, and vegetables.
- Glenmark has recalled all 928 unexpired lots of prescription ranitidine 150 mg and 300 mg tablets that can be found in the following NDCs:

Product Description	NDC#	Expiration Date Range
Ranitidine 150 mg tablets	684620-248-60; 684620-248-01; 684620-248-05	12/2019 – 5/2022
Ranitidine 300 mg tablets	684620-249-30; 684620-249-01; 684620-249-20	12/2019 – 6/2022

- Prescription ranitidine is used as a short-term treatment for active duodenal ulcers, maintenance therapy for duodenal ulcer patients, treatment of pathological hypersecretory conditions, short-term treatment of active, benign gastric ulcers, maintenance therapy for gastric ulcers, treatment of gastroesophageal reflux disease, and treatment of endoscopically diagnosed erosive esophagitis.
- Patients taking prescription ranitidine should immediately stop use and talk to their healthcare provider about other treatment options. Multiple drugs are approved for the same or similar uses as ranitidine.
- Patients should contact their physician or healthcare provider if they have experienced any problems that may be related to using the recalled ranitidine.
- Anyone with an existing inventory of the recalled product should stop distribution and quarantine the product immediately.
- The FDA continues to evaluate the safety of ranitidine and will provide more information as it becomes available. Updates can be found [here](#).
- Contact Glenmark Drug Safety at **1- 888-721- 7115** or e-mail at GlobalCustomerService@glenmarkpharma.com for further information regarding this recall.



OptumRx[®] specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum[®] company — a leading provider of integrated health services. Learn more at optum.com.

All Optum[®] trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews[®] is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.